According to filings with the U.S. Securities and Exchange Commission, Lennham Pharmaceuticals is raising $1,200,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Bradford Sippy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lennham Pharmaceuticals
We believe that deuterium chemistry is an underutilized technology that may yield products with superior metabolic or pharmacokinetic properties. Our thoughtful approach has yielded significantly improved products with strong patent protection. At Lennham, we strive to improve the metabolic and pharmacological profile of drugs through deuterium chemistry. We are a team of industry experts who believe that deuterium chemistry is an underutilized technology that may yield products with superior properties. Our thoughtful approach has yielded significantly improved products with strong patent protection. We do this by: Identifying chemical compounds that could benefit from a modification to their metabolic or pharmacokinetic properties. Generating experimental data to determine if deuterium chemistry can influence one or more metabolic or pharmacokinetic properties and support broad patent protection. Advancing products with high probability of clinical success and significant commercial potential.

To learn more about Lennham Pharmaceuticals, visit http://www.lennham.com/

Contact:
Bradford Sippy, Chief Executive Officer
617-388-7171
https://www.linkedin.com/in/brad-sippy-b7a151b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.